55
Participants
Start Date
November 14, 2019
Primary Completion Date
December 30, 2022
Study Completion Date
June 30, 2023
Radiotherapy
44.94Gy and 37.8Gy in 21 fractions to PGTV and PTV for neoadjuvant treatment. 59.92Gy and 50.4Gy in 28 fractions to PGTV and PTV for definitive treatment.
Nimotuzumab
400mg, by intravenous infusion once a week in 4-6 weeks.
S-1
40-60mg/m2/d，orally twice a day concurrently with radiotherapy.
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER